首页> 外文期刊>The American Journal of Gastroenterology >Esomeprazole compared with famotidine in the prevention of upper gastrointestinal bleeding in patients with acute coronary syndrome or myocardial infarction
【24h】

Esomeprazole compared with famotidine in the prevention of upper gastrointestinal bleeding in patients with acute coronary syndrome or myocardial infarction

机译:埃索美拉唑与法莫替丁比较预防急性冠脉综合征或心肌梗死患者上消化道出血

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Objectives: Little is known about the efficacy of proton pump inhibitors compared with H 2 receptor antagonists in preventing adverse upper gastrointestinal complications in patients with acute coronary syndrome (ACS) or ST elevation myocardial infarction (STEMI) receiving aspirin, clopidogrel, and enoxaparin or thrombolytics. The objective of this study was to compare the efficacies of esomeprazole and famotidine in preventing gastrointestinal complications. Methods: A double-blind, randomized, controlled trial was performed in patients receiving a combination of aspirin, clopidogrel, and either enoxaparin or thrombolytics. Patients received either esomeprazole (20 mg nocte) or famotidine (40 mg nocte) orally for 4-52 weeks, depending on the duration of dual antiplatelet therapy. The primary end point was upper gastrointestinal bleeding (GIB), perforation, or obstruction from ulcer/erosion (http://www.clinicaltrials.gov NCT00683111). Results: In all, 311 patients were recruited, with 163 and 148 patients in the esomeprazole and famotidine groups, respectively. Mean (s.d.) follow-up was 19.2 (17.6) and 17.6 (18.0) weeks, respectively. One (0.6%) patient in the esomeprazole group and 9 (6.1%) in the famotidine group reached the primary end point (log-rank test, P=0.0052, hazard ratio0.095, 95% confidence interval: 0.005-0.504); all had upper GIB. Conclusions: In patients with ACS or STEMI, esomeprazole is superior to famotidine in preventing upper gastrointestinal complications related to aspirin, clopidogrel, and enoxaparin or thrombolytics.
机译:目的:与使用H 2受体拮抗剂相比,质子泵抑制剂在预防接受阿司匹林,氯吡格雷和依诺肝素或溶栓剂的急性冠脉综合征(ACS)或ST抬高性心肌梗死(STEMI)患者中预防上消化道并发症的功效方面知之甚少。这项研究的目的是比较埃索美拉唑和法莫替丁在预防胃肠道并发症中的功效。方法:对接受阿司匹林,氯吡格雷,依诺肝素或溶栓药联合治疗的患者进行了一项双盲,随机,对照试验。根据双重抗血小板治疗的持续时间,患者口服艾索美拉唑(20 mg诺科特)或法莫替丁(40 mg诺科特)口服4-52周。主要终点为上消化道出血(GIB),穿孔或溃疡/糜烂阻塞(http://www.clinicaltrials.gov NCT00683111)。结果:总共招募了311例患者,其中埃索美拉唑和法莫替丁组分别为163例和148例。平均(s.d.)随访分别为19.2(17.6)和17.6(18.0)周。埃索美拉唑组1名患者(0.6%),法莫替丁组9名患者(6.1%)达到主要终点(log-rank检验,P = 0.0052,危险比0.095,95%置信区间:0.005-0.504);所有人都有上GIB。结论:在ACS或STEMI患者中,艾索美拉唑在预防与阿司匹林,氯吡格雷,依诺肝素或溶栓药相关的上消化道并发症方面优于法莫替丁。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号